Evidence map›Paper›PMID 31248002›Full record

ArticleCells2019

An

Farhana Ishrat Ghani, Kasumi Dendo, Reiko Watanabe, Kenji Yamada, Yuki Yoshimatsu, Takashi Yugawa, Tomomi Nakahara, Katsuyuki Tanaka, Hiroshi Yoshida, Masayuki Yoshida and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.International journal of molecular sciences · 2020
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Farhana Ishrat GhaniDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute; Tokyo, 104-0045, Japan. fghani@ncc.go.jp.
Kasumi DendoDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute; Tokyo, 104-0045, Japan. kootsubo@ncc.go.jp.
Reiko WatanabeDepartment of Cell Culture Technology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan. reikwata@ncc.go.jp.
Kenji YamadaDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute; Tokyo, 104-0045, Japan. keyamada@ncc.go.jp.
Yuki YoshimatsuDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute; Tokyo, 104-0045, Japan. yyoshima@ncc.go.jp.
Takashi YugawaDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute; Tokyo, 104-0045, Japan. tyugawa@ncc.go.jp.
Tomomi NakaharaDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute; Tokyo, 104-0045, Japan. tonakaha@ncc.go.jp.
Katsuyuki TanakaDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute; Tokyo, 104-0045, Japan. kattanak@ncc.go.jp.
Hiroshi YoshidaPathology Division, National Cancer Center Hospital, Tokyo, 104-0045, Japan. hiroyosh@ncc.go.jp.
Masayuki YoshidaPathology Division, National Cancer Center Hospital, Tokyo, 104-0045, Japan. masayosh@ncc.go.jp.
Mitsuya IshikawaDepartment of Gynecology, National Cancer Center Hospital, Tokyo, 104-0045, Japan. miishika@ncc.go.jp.
Naoki GoshimaMolecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan. n-goshima@aist.go.jp.
Tomoyasu KatoDepartment of Gynecology, National Cancer Center Hospital, Tokyo, 104-0045, Japan. tokato@ncc.go.jp.
Tohru KiyonoDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute; Tokyo, 104-0045, Japan. tkiyono@ncc.go.jp.
Genesis Research Institute · JPNational Cancer Centre Japan · JPTokyo National Hospital · JPNational Institute of Advanced Industrial Science and Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The success rate of establishing human cancer cell lines is not satisfactory and the established cell lines often do not preserve the molecular and histological features of the original tissues. In this study, we developed a novel culture method which can support proliferation of almost all primary epithelial ovarian cancer cells, as well as primary normal human oviductal epithelial cells. Cancer cells from fresh or frozen specimens were enriched by the anti-EpCAM antibody-conjugated magnetic beads, plated on Matrigel-coated plate and cultivated under the optimized culture conditions. Seventeen newly established ovarian cancer cell lines, which included all four major histotypes of ovarian cancer, were confirmed to express histotype-specific markers

Indexed as

AdultCarcinoma, Ovarian EpithelialCell Line, TumorCystadenoma, MucinousEctopic Gene ExpressionFemaleHumansMiddle AgedOncogenesOvarian NeoplasmsOvaryPrimary Cell CultureXenograft Model Antitumor Assayscell cultureovarian cancerxenograft

Identifiers

PMID31248002
PMCPMC6678777
OpenAlexW2954044984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.